Drug – bio-affecting and body treating compositions – Lymphokine
Patent
1998-02-27
2000-07-25
Wortman, Donna C.
Drug, bio-affecting and body treating compositions
Lymphokine
424 943, 4241821, 424 7818, 514 3, 514723, A61K 4508, A61K 3174, A61K 3828
Patent
active
060933917
ABSTRACT:
Compositions of peptides and block copolymers and methods of treatment using the same. The compositions enhance the activity of peptide-based and related biological agents, and reduce adverse side effects.
REFERENCES:
patent: 4027013 (1977-05-01), Bick et al.
patent: 4106474 (1978-08-01), Hunter et al.
patent: 4188373 (1980-02-01), Krezanoski
patent: 4337760 (1982-07-01), Rubin
patent: 4474752 (1984-10-01), Haslam et al.
patent: 4481195 (1984-11-01), Rubin
patent: 4485457 (1984-11-01), Balaska et al.
patent: 4609546 (1986-09-01), Hiratani
patent: 4740498 (1988-04-01), Hirao et al.
patent: 4772466 (1988-09-01), Alison et al.
patent: 4801452 (1989-01-01), Hunter et al.
patent: 4837014 (1989-06-01), Hunter et al.
patent: 4865835 (1989-09-01), Begent
patent: 4873083 (1989-10-01), Hunter et al.
patent: 4879109 (1989-11-01), Hunter
patent: 4882168 (1989-11-01), Casey et al.
patent: 4897263 (1990-01-01), Hunter
patent: 4937070 (1990-06-01), Hunter
patent: 4957735 (1990-09-01), Huang
patent: 4990538 (1991-02-01), Harris et al.
patent: 4997644 (1991-03-01), Hunter
patent: 5005588 (1991-04-01), Rubin
patent: 5017370 (1991-05-01), Hunter et al.
patent: 5028599 (1991-07-01), Hunter
patent: 5030448 (1991-07-01), Hunter
patent: 5032394 (1991-07-01), Hunter
patent: 5039520 (1991-08-01), Hunter
patent: 5039527 (1991-08-01), Tabibi et al.
patent: 5041288 (1991-08-01), Hunter
patent: 5047236 (1991-09-01), Hunter et al.
patent: 5064643 (1991-11-01), Hunter et al.
patent: 5071649 (1991-12-01), Hunter
patent: 5078995 (1992-01-01), Hunter et al.
patent: 5080894 (1992-01-01), Hunter et al.
patent: 5089260 (1992-02-01), Hunter et al.
patent: 5114708 (1992-05-01), Hunter et al.
patent: 5143731 (1992-09-01), Viegas et al.
patent: 5152979 (1992-10-01), Hunter
patent: 5182106 (1993-01-01), Mezrow et al.
patent: 5183687 (1993-02-01), Hunter et al.
patent: 5198211 (1993-03-01), Hunter et al.
patent: 5234683 (1993-08-01), Hunter et al.
patent: 5240701 (1993-08-01), Hunter et al.
patent: 5240702 (1993-08-01), Hunter et al.
patent: 5250294 (1993-10-01), Hunter et al.
patent: 5412072 (1995-05-01), Sakurai et al.
patent: 5417982 (1995-05-01), Modi
patent: 5436170 (1995-07-01), Cornell et al.
patent: 5449513 (1995-09-01), Yokoyama et al.
patent: 5466445 (1995-11-01), Hunter
patent: 5470568 (1995-11-01), Lee
patent: 5488034 (1996-01-01), McGregor et al.
patent: 5494660 (1996-02-01), Hunter et al.
patent: 5523492 (1996-06-01), Emanuele et al.
patent: 5554372 (1996-09-01), Hunter
patent: 5567859 (1996-10-01), Emanuele et al.
patent: 5591715 (1997-01-01), Coon et al.
patent: 5622649 (1997-04-01), Hunter et al.
patent: 5648071 (1997-07-01), Hunter et al.
patent: 5656611 (1997-08-01), Kabanov et al.
patent: 5674911 (1997-10-01), Emanuele et al.
patent: 5691387 (1997-11-01), Emanuele et al.
patent: 5696090 (1997-12-01), McGregor et al.
patent: 5696298 (1997-12-01), Emanuele et al.
patent: 5698529 (1997-12-01), Alakhov et al.
patent: 5776891 (1998-07-01), Coon et al.
patent: 5817321 (1998-10-01), Alakhov et al.
patent: 5840319 (1998-11-01), Alakhov et al.
patent: 5885590 (1999-03-01), Hunter
Chekhonin et al., Fatty acid acylated Fab-fragments of antibodies to neurospecific proteins as carriers for neuroleptic targeted delivery in brain. FEBS Letters 287(1,2):149-152, 1991.
Kabanov et al., "The Neuroleptic Activity of Haloperidol Increases After Its Solubilization In Surfactant Micelles: Micelles As Microcontainers For Drug Targeting", FEBS Lett., 258, N 2, 343-345 (1989).
Kabanov et al., "A New Class of Drug Carriers: Micelles Of Poly(oxyethylene)--Poly(oxypropylene) Block Copolymers As Microcontainers For Drug Targeting From Blood In Brain", J. Contr. Release, 22, 141-158 (1992).
Kabanov et al., "Enhancement Of Macromolecule Penetration Into Cells And Nontraditional Drug Delivery Systems", Sov. Sci. Rev. D. Physicochem. Biol. (V.P. Skulachev ed.), vol. 11, Glasgow: Harwood Academic Publishers, part 2, pp. 1-77 (1992).
Kabanov et al., "Site Specific Drug Targeting", CPhI '92 Conference Proceedings, London: Eyre & Spotiswoode Ltd., pp. 89-96 (1993).
Kabanov et al., Polymeric Surfactant Micelles As Microcontainers . . . , Journal of Neuroimmuno. (Suppl 1): 130 (1991).
Chawla et al., "Aggregation of Insulin, Containing Surfactants, in Contact with Different Materials," Diabetes. vol. 34: 420-424 (1995).
Kabanov et al., "Interpolyelectrolyte and Block Ionomer Complexes for Gene Delivery: Physicochemic Aspects," Advanced Drug Delivery Reviews, Elsevier, vol. 30: 49-60 (1998).
Batrakova, "Effects of Pluronic Block Copolymers on Drug Absorption in Caco-2 Cell Monolayers," Pharmaceutical Research, vol. 15, No. 6, (1998).
Abstract, Database WPI Week 9519, Derwent Publ. Ltd. AN 95-144714 High Water Soluble Antitumor Adriamycin Agent Comprise Micellar Complex Block Copolymer Polyethylene Glycol Poly Amino acid.
Kataoka et al., "Block Copolymer Micelles As Vehicles for Drug Delivery," Journal of Controlled Release, vol. 24: 119-132 (1993).
Paradis et al. "Use of pluronic micelles to overcome multidrug resistance" Int. J. Oncology 5:1305-08 (1994).
Lin, Shan-Yang et al., "In vitro release, pharmacokinetic and tissue distribution studies of doxorubicin hydrochloride (Adriamycin HCl.RTM.) encapsulated in lipiodolized w/o enulsions and w/o/w multiple emulsions." Pharmazie 47:439-443 (Jun. 1992).
Derwent WPI AN 84-265868 (DW8443), Abstract of Japanese patent application JP 59161313 "Carcinostatic-contig. adding emulsion preparation by mixing carcinostatics, oils and 1 or more of tocopherol(s) or ubiquinone(s) and emulsifiers". Sep. 1984.
Derwent WPI AN 84-013559 (DW8403) Abstract of Japanese patent application JP48088220 "Lymph node-directing carcinostat(s) comprise emulsion of carcinostatic agent, oil and fat prepared by ultrasonic treatment" Nov. 1973.
Bradley et al., "P-Glycoprotein Expression in Multidrug-resistant Human Ovarian Carcinoma Cell Lines", Cancer Research, 49:2790-2796 (1989).
Hamada et al., "Functional Role for the 170--to 180-kDa Glycoprotein Specific to Drug-Resistant Tumor Cells as Revealed by Monoclonal Antibodies", PNAS-USA, 83:7785-7789 (1986).
Kabanov et al., "A New Way in Homogeneous Immunoassay: Reversed Micellar Systems as a Medium for Analysis", Anal. Biochem., 181:145-148 (1989).
Kabanov et al., "Lipid Modification of Proteins and Their Membrane Transport", Protein Eng., 3(1):39-42 (1989).
Kabanov et al., "The Neuroleptic Activity of Haloperidol Increases After its Solubilization in Surfactant Micelles", FEBS Lett., 258(2):343-345.
Kabanov et al., "A New Class of Drug Carriers: Micelles Of Poly(oxyethylene)-poly(oxypropylene) Block Copolymers As Microcontainers For Drug Targeting From Blood In Brain", Journal of Controlled Release, 22:141-157 (1992).
Kabanov et al., "Enhancement Of Macromolecule Penetration Into Cells And Nontraditional Drug Delivery Systems", Sov. Sci. Rev. D. Physicochem. Biol., 11:1-75 (1992).
Kartner et al., "Multidrug Resistance in Cancer", Scientific American, pp. 44-51 (Mar. 1989).
Rivoltini et al., "Modulation of Multidrug Resistance by Verapamil or mdrl Anti-Sense Oligodeoxynucleotide Does Not Change the High Susceptibility to Lymphokine-Activated Killers in mdr-resistant Human Carcinoma (LoVo) Line", Int. J. Cancer, 46:727-732 (1990).
Rogan et al., "Reversal of Adriamycin Resistance by Verapamil in Human Ovarian Cancer", Science, 224:994-996 (1984).
Slepnev et al., "Micelles of Poly(oxypropylene) Block Copolymer (Pluronic) as a Tool for Low-Molecular Compound Delivery into a Cell: Phosphorylation of Intracellular Proteins with Micelle Incorporated [.gamma.-.sup.32 P]ATP.sup.1 ", Biochemistry International, vol. 26, No. 4:587-595 (1992).
Alakhov Valery Y.
Kabanov Alexander V.
Supratek Pharma Inc.
Wortman Donna C.
LandOfFree
Peptide copolymer compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptide copolymer compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide copolymer compositions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1334633